WO1991000729A3 - Bis-dioxopiperazines, et leur utilisation en tant qu'agents de protection - Google Patents

Bis-dioxopiperazines, et leur utilisation en tant qu'agents de protection Download PDF

Info

Publication number
WO1991000729A3
WO1991000729A3 PCT/GB1990/001079 GB9001079W WO9100729A3 WO 1991000729 A3 WO1991000729 A3 WO 1991000729A3 GB 9001079 W GB9001079 W GB 9001079W WO 9100729 A3 WO9100729 A3 WO 9100729A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
group
carbon atoms
maximum
aliphatic hydrocarbon
Prior art date
Application number
PCT/GB1990/001079
Other languages
English (en)
Other versions
WO1991000729A2 (fr
Inventor
Andrew Malcolm Creighton
Original Assignee
Nat Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Dev filed Critical Nat Res Dev
Publication of WO1991000729A2 publication Critical patent/WO1991000729A2/fr
Publication of WO1991000729A3 publication Critical patent/WO1991000729A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention se rapporte à des composés représentés par la formule (II); où n est égal à 0, à 1 ou à 2; R1, R2, R3 et R4 sont chacun choisis séparément parmi l'hydrogène, des groupes d'hydrocarbures aliphatiques acycliques non substitués ayant un maximum de six atomes de carbone et des groupes alkyle de 1 à 6 atomes de carbone substitués par un groupe hydroxy ou un groupe alkoxy de 1 à 6 atomes de carbone, ou l'un des éléments R1 et R2 et l'un des éléments R3 et R4 représentent l'hydrogène et les autres représentent un groupe de liaison en pont triméthylène, tétraméthylène ou pentaméthylène; et R5 représente l'hydrogène ou un groupe d'hydrocarbure aliphatique acyclique non substitué ayant un maximum de six atomes de carbone; à condition, toutefois, que: (a) lorsque n est égal à 0, les combinaisons R1 = R2 = R3 = R4 = R5 = H et R1 = R2 = R3 = R5 = H, R4 = méthyle sont exclues, et (b) lorsque n est égal à 0, que R1, R3 et R5 représentent chacun l'hydrogène et chacun des éléments R2 R4 est autre que l'hydrogène, le composé présente une configuration autre que la configuration méso ou érythro; ou à un sel d'un tel composé formé avec un acide inorganique ou organique physiologiquement acceptable, ledit composé ou son sel ayant une utilité thérapeutique, notamment comme agents cardioprotecteurs.
PCT/GB1990/001079 1989-07-13 1990-07-13 Bis-dioxopiperazines, et leur utilisation en tant qu'agents de protection WO1991000729A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898916072A GB8916072D0 (en) 1989-07-13 1989-07-13 Pharmaceutical compositions
GB8916072.5 1989-07-13

Publications (2)

Publication Number Publication Date
WO1991000729A2 WO1991000729A2 (fr) 1991-01-24
WO1991000729A3 true WO1991000729A3 (fr) 1991-06-13

Family

ID=10660005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1990/001079 WO1991000729A2 (fr) 1989-07-13 1990-07-13 Bis-dioxopiperazines, et leur utilisation en tant qu'agents de protection

Country Status (8)

Country Link
EP (1) EP0409499A3 (fr)
JP (1) JPH04500690A (fr)
AU (1) AU6047190A (fr)
CA (1) CA2033203A1 (fr)
GB (2) GB8916072D0 (fr)
NZ (1) NZ234459A (fr)
WO (1) WO1991000729A2 (fr)
ZA (1) ZA905511B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3050598B2 (ja) * 1990-07-04 2000-06-12 全薬工業株式会社 水溶性ビスージオキソピペラジン誘導体
GB9015435D0 (en) * 1990-07-13 1990-08-29 Creighton Andrew M Pharmaceutical compositions
GB9115596D0 (en) * 1991-07-12 1991-09-04 Creighton Andrew M Pharmaceutical compositions
GB9122677D0 (en) * 1991-10-25 1991-12-11 Eurocetus Bv Process for preparing(s)(+)-4,4'-(1-methyl-1,2-ethanediyl)-bis(2,6-piperazinedione)
US5760039A (en) * 1991-10-25 1998-06-02 Chiron Corporation Lyophilized composition containing S(+)-4,4'-(1-methyl-1,2-ethanediyl)-bis(2,6-piperazinedione)
GB9124483D0 (en) * 1991-11-18 1992-01-08 Windleshaw Enterprises Ltd Bis(3,5-dioxoalkylpiperazine)derivatives for use in treating intracellular accumulation of metal ions
WO1995003054A1 (fr) * 1993-07-23 1995-02-02 Lxr Biotechnology Inc. Procedes de traitement de l'apoptose et d'etats associes
US6265385B1 (en) * 1996-01-11 2001-07-24 Topo Target Aps Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196153A (en) * 1961-01-19 1965-07-20 Geigy Chem Corp Poly(3, 5-diketo-piperazinyl-1) compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234935A (en) * 1967-07-03 1971-06-09 Nat Res Dev Piperazine derivatives
GB1374979A (en) * 1970-12-21 1974-11-20 Nat Res Dev 3,5-dioxopiperazine derivatives
DE1967027C3 (de) * 1968-07-02 1978-06-22 National Research Development Corp., London Bis-<33-dioxopiperazino)-alkanverbindungen und Verfahren zu ihrer Herstellung
NL163957C (nl) * 1968-07-02 1980-11-17 Nat Res Dev Werkwijze voor het bereiden van een geneesmiddel tegen kanker, alsmede werkwijze voor het bereiden van een 1,2-di(3,5-dioxopiperazinoalkaanverbinding.
GB1236947A (en) * 1968-08-15 1971-06-23 Ici Ltd Process for the preparation of piperazine derivatives
FR2278324A1 (fr) * 1974-07-18 1976-02-13 Bottu Nouveaux derives du paracetamol
DE2511892A1 (de) * 1975-03-19 1976-10-07 Gruenenthal Chemie Arzneimittel
DE2511891A1 (de) * 1975-03-19 1976-10-07 Gruenenthal Chemie Neue derivate des 2,6-dioxopiperazins, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel sowie verfahren zu deren herstellung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196153A (en) * 1961-01-19 1965-07-20 Geigy Chem Corp Poly(3, 5-diketo-piperazinyl-1) compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Advances in Pharmacology and Chemotherapy, vol. 19, 1982, Academic Press, Inc., E.H. Herman et al.: "Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds", pages 249-290 see the whole article; especially page 251, compounds 13,14; page 252, compound 17; page 253, compound 19 *
Dev. Oncolog., vol. 53, 1988, V.J. Ferrans et al.: "Pretreatment with ICRF-187 protects against the chronic cardiac toxicity produced by very large cumulative dosis of doxorubicin in beagle dogs", pages 56-63 *
Med. Chem. Proc. Int. Symp. 6th, 1978, A.M. Creighton et al.: "Bisdioxopiperazines", pages 281-288 *
Research Communications in Chemical Pathology and Pharmacology, vol. 33, no. 3, September 1981, A.N. El-Hage et al.: "Reduction in the diabetogenic effect of alloxan in mice by treatment with the antineoplastic agent ICRF-187", pages 509-523 *
Research communications in Chemical Pathology and Pharmacology, vol. 48, no. 1, April 1985, E.H. Herman et al.: "Comparison of the protective effect of ICRF-187 and structurally related analogues against acute daunorubicin toxicity in Syrian golden hamsters", pages 35-55 *
Toxicology, vol. 28, 1983, Elsevier Scientific Publishers Ireland Ltd, (IE), A.N. El-Hage et al.: "Examination of the protective effect of ICRF-187 and dimethyl sulfoxide against acetaminopheninduced hepatotoxicity in Syrian golden hamsters", pages 295-303 see summary; page 299, table II *

Also Published As

Publication number Publication date
EP0409499A3 (en) 1991-03-27
GB2235874A (en) 1991-03-20
GB9015437D0 (en) 1990-08-29
NZ234459A (en) 1992-04-28
EP0409499A2 (fr) 1991-01-23
WO1991000729A2 (fr) 1991-01-24
JPH04500690A (ja) 1992-02-06
CA2033203A1 (fr) 1991-01-14
GB8916072D0 (en) 1989-08-31
AU6047190A (en) 1991-02-06
ZA905511B (en) 1992-03-25

Similar Documents

Publication Publication Date Title
HU9203304D0 (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues
PL285756A1 (en) Method of obtaining novel condensed heterocyclic compounds
NZ220546A (en) Benzothiophene- and benzofuran- amides and compositions
NO904377D0 (no) Tricykliske karbapenemforbindelser.
HK1011980A1 (en) 1-Methylcarbapenem derivatives their preparation and their use as antibiotics
IL94027A0 (en) Diaminoethylene compounds
WO1991000729A3 (fr) Bis-dioxopiperazines, et leur utilisation en tant qu&#39;agents de protection
NO921159D0 (no) Tiazolidinon- og oksazolidinonderivater, fremgangsmaate til fremstilling derav, samt anvendelse av derivatene som vasodilatorer
MX170732B (es) Composicion de derivados de succinimida y su uso
EP0601191A4 (en) Novel tetracyclic compound.
ATE146476T1 (de) Cephalosporinverbindungen und verfahren zu ihrer herstellung
MY106839A (en) Carboxylate compounds, liquid crystal compositions containing said compounds and liquid crystal elements.
WO1992000740A3 (fr) Bis-dioxopiperazines et leur utilisation en tant qu&#39;agents protecteurs
CA2308315A1 (fr) N,n&#39;-bis (sulfonyl)hydrazines utilisees comme agents antineoplasiques
IE892294L (en) Cycloalkylthiazole derivatives
UA41340C2 (uk) Похідні циклогексанкарбонової кислоти, суміш їх ізомерів або окремі ізомери і фізіологічно прийнятні солі і фармацевтична композиція з активністю, що гальмує ферментний комплекс глюкоза-6-фосфатази
IL74533A (en) Pharmaceutical compositions comprising piperidine derivatives,some novel pieridine derivatives and method for the preparation thereof
DK0538517T3 (da) Nye organo-tinforbindelser med antitumoraktivitet og antitumormidler
FI883507A0 (fi) Naftotiazepinderivat och deras framstaellning.
EP0230474A4 (fr) Derives de bis-dioxopiperazine et compositions de medicaments les contenant.
AU8716391A (en) Tri(lower alkoxy)benzene derivative
SE8700366D0 (sv) Medel vid lungfibros
TH13791EX (th) อนุพันธ์ต่างๆของกรดบิวไทริค
TH13791A (th) อนุพันธ์ต่างๆของกรดบิวไทริค
TH13348EX (th) อนุพันธ์ 1-เมธิลคาร์แบพีเนม การเตรียมสารเหล่านั้นและการใช้สารเหล่านั้นเป็นสารปฏิชีวนะ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

WWE Wipo information: entry into national phase

Ref document number: 2033203

Country of ref document: CA

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US